Halsey Associates Inc. CT raised its stake in Pfizer Inc. (NYSE:PFE) by 74.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 45,042 shares of the biopharmaceutical company’s stock after acquiring an additional 19,168 shares during the period. Halsey Associates Inc. CT’s holdings in Pfizer were worth $1,966,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Advocacy Wealth Management Services LLC lifted its stake in shares of Pfizer by 48.2% in the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 258 shares during the period. Winch Advisory Services LLC lifted its stake in shares of Pfizer by 69.6% in the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 336 shares during the period. 1 North Wealth Services LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $40,000. Ruggie Capital Group acquired a new position in shares of Pfizer in the 4th quarter valued at about $44,000. Finally, Contravisory Investment Management Inc. lifted its stake in shares of Pfizer by 182.6% in the 4th quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 745 shares during the period. Hedge funds and other institutional investors own 71.88% of the company’s stock.
A number of research analysts have recently issued reports on PFE shares. Cantor Fitzgerald reissued a “buy” rating and issued a $53.00 price objective on shares of Pfizer in a research note on Tuesday, February 19th. Citigroup reissued a “neutral” rating and issued a $41.00 price objective on shares of Pfizer in a research note on Wednesday, February 20th. Zacks Investment Research downgraded Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday, March 28th. Bank of America boosted their price objective on Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a $46.00 price objective on shares of Pfizer in a research note on Friday, April 19th. Thirteen research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $46.00.
In other news, major shareholder Pfizer Inc purchased 50,000 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were acquired at an average cost of $17.00 per share, with a total value of $850,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $42.83, for a total value of $642,450.00. Following the transaction, the insider now directly owns 124,994 shares in the company, valued at $5,353,493.02. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by corporate insiders.
PFE stock opened at $42.50 on Friday. Pfizer Inc. has a fifty-two week low of $35.73 and a fifty-two week high of $46.47. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.27 and a current ratio of 1.54. The company has a market cap of $239.52 billion, a P/E ratio of 14.17, a PEG ratio of 2.49 and a beta of 0.65.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. Pfizer had a return on equity of 27.48% and a net margin of 21.31%. The business had revenue of $13.12 billion for the quarter, compared to the consensus estimate of $13.01 billion. During the same period in the prior year, the business earned $0.77 EPS. The firm’s revenue for the quarter was up 1.6% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, June 7th. Investors of record on Friday, May 10th were paid a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date was Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.
ILLEGAL ACTIVITY WARNING: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2019/06/14/halsey-associates-inc-ct-raises-position-in-pfizer-inc-nysepfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: What is the float in trading stocks?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.